MIM Software’s MAA SPECT/CT Dosimetry for MIM SurePlan LiverY90 Product Approved in Europe

August 5, 2021—MIM Software Inc., a provider of medical imaging software, announced it has received European CE Mark approval for macroaggregated albumin (MAA) voxel-based single-photon emission CT (SPECT)/CT dosimetry through its MIM SurePlan LiverY90 product. MIM Software Inc. is a privately held company headquartered in Cleveland, Ohio, with offices in Brussels, Belgium as well as Beijing and Chengdu, China.

According to the company, MIM SurePlan LiverY90 provides pretreatment activity planning, time-saving tools for liver and tumor segmentation, deformable registration, and posttreatment dosimetry for interventional radiologists and nuclear medicine physicians treating hepatic tumors with radioactive microspheres, including SIR-Spheres Y-90 resin microspheres (Sirtex Medical). The software allows physicians to quickly calculate the dose delivered by the microspheres to improve treatment decisions and patient care.

MIM Software stated that the CE Mark approval expands upon the company’s partnership with Sirtex announced in February 2020 that authorized specialized Sirtex sales teams in the United States, Europe, and other key global markets to offer a comprehensive solution, InsyteY90, that includes MIM SurePlan LiverY90 alongside SIR-Spheres Y-90 resin microspheres to improve treatment precision for patients with hepatic tumor.

In the European Union, Sirtex SIR-Spheres Y-90 resin microspheres are approved for the treatment of inoperable liver tumors. In the United States, SIR-Spheres Y-90 received FDA approval for the treatment of nonresectable metastatic liver tumors from primary colorectal cancer in combination with intrahepatic artery chemotherapy using floxuridine, noted the announcement.